These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 17953871)
1. [Hereditary breast cancer: treatment and prevention]. Ejlertsen B; Gerdes AM Ugeskr Laeger; 2007 Sep; 169(36):2972-5. PubMed ID: 17953871 [TBL] [Abstract][Full Text] [Related]
2. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145 [TBL] [Abstract][Full Text] [Related]
3. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241 [TBL] [Abstract][Full Text] [Related]
4. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443 [TBL] [Abstract][Full Text] [Related]
5. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. Schrag D; Kuntz KM; Garber JE; Weeks JC N Engl J Med; 1997 May; 336(20):1465-71. PubMed ID: 9148160 [TBL] [Abstract][Full Text] [Related]
6. Hereditary ovarian cancer--assessing risk and prevention strategies. Pavelka JC; Li AJ; Karlan BY Obstet Gynecol Clin North Am; 2007 Dec; 34(4):651-65, vii-viii. PubMed ID: 18061862 [TBL] [Abstract][Full Text] [Related]
7. Perspectives in the clinical management of BRCA mutations carriers. Savarese A; Cognetti F J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):31-5. PubMed ID: 12585651 [TBL] [Abstract][Full Text] [Related]
8. Hereditary breast-ovarian cancer: clinical findings and medical management. Marshall M; Solomon S Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820 [TBL] [Abstract][Full Text] [Related]
9. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Roukos DH; Briasoulis E Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808 [TBL] [Abstract][Full Text] [Related]
10. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA; J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327 [TBL] [Abstract][Full Text] [Related]
11. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation. Metcalfe KA; Foulkes WD; Kim-Sing C; Ainsworth P; Rosen B; Armel S; Poll A; Eisen A; Gilchrist D; Chudley A; Ghadirian P; Maugard C; Lemire EG; Sun P; Narod SA Clin Genet; 2008 May; 73(5):474-9. PubMed ID: 18341607 [TBL] [Abstract][Full Text] [Related]
12. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy. Dowdy SC; Stefanek M; Hartmann LC Am J Obstet Gynecol; 2004 Oct; 191(4):1113-23. PubMed ID: 15507929 [TBL] [Abstract][Full Text] [Related]
13. Strategies for ovarian cancer prevention. Dann RB; Kelley JL; Zorn KK Obstet Gynecol Clin North Am; 2007 Dec; 34(4):667-86, viii. PubMed ID: 18061863 [TBL] [Abstract][Full Text] [Related]
14. The prevention of hereditary breast cancer. Rodriquez E; Domchek SM Semin Oncol; 2007 Oct; 34(5):401-5. PubMed ID: 17920894 [TBL] [Abstract][Full Text] [Related]
16. Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations". Olivier RI; van Beurden M Gynecol Oncol; 2005 Nov; 99(2):520-1. PubMed ID: 16188301 [No Abstract] [Full Text] [Related]
17. BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use. Grenader T; Peretz T; Lifchitz M; Shavit L Breast; 2005 Aug; 14(4):264-8. PubMed ID: 16085232 [TBL] [Abstract][Full Text] [Related]
18. Breast and ovarian cancer genetics and prevention. Altaha R; Reed E; Abraham J W V Med J; 2003; 99(5):187-91. PubMed ID: 14959510 [TBL] [Abstract][Full Text] [Related]
19. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Schmeler KM; Sun CC; Bodurka DC; White KG; Soliman PT; Uyei AR; Erlichman JL; Arun BK; Daniels MS; Rimes SA; Peterson SK; Slomovitz BM; Milam MR; Gershenson DM; Lu KH Obstet Gynecol; 2006 Sep; 108(3 Pt 1):515-20. PubMed ID: 16946209 [TBL] [Abstract][Full Text] [Related]
20. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]